---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-114520"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:39:05.623291+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Celldex announces positive Phase 2 CSU data for barzolvolimab; $12.5M milestone triggered

## Summary
- Barzolvolimab met primary endpoint: LS mean UAS7 change from baseline to week 12 was -23.87 (300mg q8w) vs -10.47 placebo (p<0.0001).
- Complete control (UAS7=0) at week 12: 37.5% (300mg q8w), 51.1% (150mg q4w), 22.9% (75mg q4w) vs 6.4% placebo.
- Positive Phase 2 data triggers $12.5M milestone payment under settlement agreement with SRS, to be paid in cash.
- Phase 1B data in prurigo nodularis showed meaningful itch reduction and clear/almost clear skin with single 3.0 mg/kg dose.

## SEC filing metadata
- accession: 0001104659-23-114520
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000110465923114520/0001104659-23-114520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000110465923114520/tm2329928d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-114520
- JSON: https://secwatch.observer/filing/0001104659-23-114520.json
- Plain text: https://secwatch.observer/filing/0001104659-23-114520.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.